Pause points · review the gaps
Which offers deserve a second look?
An answer can sound certain while leaving the central question open.
What is still unknown?
By September 28, 2026, the Food and Drug Administration (FDA) had no studies of KPV use in people to judge its unwanted effects.
It also found no animal tests of long-term harm or effects on pregnancy.
The September 2026 review found no FDA-reviewed KPV label telling patients who must avoid it or which medicines might cause problems together.
Which claims go beyond what is known?
- A proven gut treatment
KPV’s gut findings came from mice and cells; the September 2026 review found no studies treating people with bowel disease.
- A natural-sounding name
KPV matches part of a hormone, a chemical messenger in the body; that match does not prove it is safe.
- Compounding described as approval
When a pharmacy prepares a medicine from ingredients, that work is called compounding.
As checked on September 26, 2026, compounding a medicine did not give it FDA approval.
FDA does not confirm a compounded product’s quality before sale, or establish its safety or how well it works.
- A drug number offered as proof
As checked in September 2026, a National Drug Code marked an entry in FDA’s drug list; it did not mean approval.
If an offer points to that number, ask to see the actual approval rather than accepting the number as proof.
Did a withdrawn request change the rules?
On FDA’s ingredient page, marked current on April 22, 2026, KPV appears under “nominated but withdrawn”.
That wording means the request to allow the ingredient was taken back; it does not mean FDA cleared KPV.
For pharmacies filling individual prescriptions, US federal rules checked on September 26, 2026, did not allow KPV as a raw ingredient.
It was not on the permitted ingredient list or part of an FDA-approved drug, and no official written standard for the raw substance applied.
Those findings do not change just because a pharmacy offers to make a KPV product.
Ask the pharmacy to name the law it relies on and show how its KPV product meets that law.
If there is a problem, where can I turn?
Severe symptoms of an allergic reaction need emergency help; MedlinePlus includes a swollen tongue and difficulty breathing among the signs.
Patients can report a suspected problem with a medicine through FDA’s MedWatch service.
Open MedWatch’s reporting informationContinue the reading path
Take the questions into a conversation.
Bring the questions that remain open and ask how the proposed care addresses the health concern.